Abstract: In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
April 23, 2024
Assignee:
Cellphire, Inc.
Inventors:
Keith Andrew Moskowitz, Rafael Jorda, Ying Yi Zheng, Daniel Allen Sheik
Abstract: A process of recovering oil, comprising (a) converting a starch-containing material into dextrins with an alpha-amylase; (b) saccharifying the dextrins using a carbohydrate source generating enzyme to form a sugar; (c) fermenting the sugar in a fermentation medium into a fermentation product using a fermenting organism; (d) recovering the fermentation product to form a whole stillage; (e) separating the whole stillage into thin stillage and wet cake; (e?) optionally concentrating the thin stillage into syrup; (f) recovering oil from the thin stillage and/or optionally the syrup, wherein a protease and a phospholipase are present and/or added during steps (a) to (c). Use of a protease and a phospholipase for increasing oil recovery yields from thin stillage and/or syrup in a fermentation product production process.
Type:
Grant
Filed:
May 3, 2021
Date of Patent:
June 13, 2023
Assignee:
NOVOZYMES A/S
Inventors:
Joseph Jump, Nathaniel Edward Kreel, Bernardo Vidal, Jr., Chee-Leong Soong, Madison Roberts, Melissa Carrie Hooss, Xinyu Shen
Abstract: Methods for decellularizing organs and tissues in vitro and in vivo are provided, as are methods of maintaining organ and tissue frameworks and methods of recellularizing organs and tissues, thereby providing an approach to needed organs or tissues.
Abstract: The present disclosure relates to proteases having an amino acid sequence with at least 70% sequence identity to the amino acid sequence given in SEQ ID No. 1, across its whole length, and comprising an amino acid substitution on at least one of the positions P9, Q10, Q62, L82, P86, N130, T141, N187, S236 or T253, relating in each case to the numbering according to SEQ ID No. 1. The present disclosure also relates to the production and use thereof. Said type of proteases have a very good cleaning performance.
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
December 27, 2022
Assignee:
HENKEL AG & CO. KGAA
Inventors:
Nina Mussmann, Timothy O'Connell, Daniela Herbst, Inken Prueser, Christian Degering, Sabine Griemert, Thorsten Eggert, Christian Leggewie
Abstract: A truncated and modified Serratiopeptidase or a variant thereof, and polynucleotides encoding the same. The truncated and modified Serratiopeptidase may have an amino acid sequence including amino acids 1 to 344, and amino acids 1 to 380 of SEQ ID NO: 1. The truncated and modified Serratiopeptidase may further include a first Cysteine (C) residue at a N-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Alanine 8 and Leucine 12 of SEQ ID NO: 1; and a second Cysteine residue at a C-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Valine 339 and Arginine 302 of SEQ ID NO: 1. The first and the second Cysteine residues may be adapted to form at least one disulfide bond including at least one of C8-C339, and C12-C302 disulfide bonds between the N-terminus and the C-terminus of the truncated and modified Serratiopeptidase.
Abstract: A phosphate-free automatic dishwashing cleaning composition comprising a protease wherein the protease has at least 80%, preferably at least 85%, more preferably at least 90% and especially at least 96% identity with the amino acid sequence of SEQ ID NO:1 or with the amino acid sequence of SEQ ID NO:2 and wherein the protease comprises amino acid substitutions selected from the group consisting of: (i) at least two amino acid substitutions selected from the group consisting of: X198G/A/K/L/Q/R/T/V/S/L, X207Q, X211Q/N and X212Q in combination with at least three amino acid substitutions selected from the group consisting of: X039E, X074D, X099R, X126A, X127E and X128G; or (ii) X039E-X074D-X099R-X116R-X126A-X127E-X128G-X211Q; X039E-X074D-X099R-X126A-X127E-X128G-X211N; X039E-X074D-X099R-X126A-X127E-X128G-X211Q; X039E-X074D-X099R-X126A-X127E-X128G-X207Q; or (iii) any of the proteases of (i) and (ii) further comprising at least one amino acid substitution selected from X242D and X256E; or (iv) X039E-X074D-X099R
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
November 8, 2022
Assignee:
The Procter & Gamble Company
Inventors:
Philip Frank Souter, Eva Maria Perez-Prat Vinuesa, Michelle Jackson, Carly Pickering, Viktor Yuryevich Alekseyev, Lilia Maria Babe, Frits Goedegebuur, Thijs Kaper, Sina Pricelius, Sander Van Stigt Thans, Harm Mulder, Nils Henning Redestig, Lydia Dankmeyer, Michael Stoner, Adam Garske, Roopa Santosh Ghirnikar
Abstract: The present invention relates to protease variants, having improved properties compared to the parent protease, in particular variants of a serine protease belonging to family 53 derived from a strain of Meripilus giganteus. The variants according to the invention have in particular increased thermo-stability, e.g., increased residual activity after 30 min at a temperature in the range from 55 to 60° C. and/or increased thermal denaturation temperature, compared to the parent Meripilus giganteus protease. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Grant
Filed:
January 14, 2021
Date of Patent:
September 20, 2022
Assignee:
NOVOZYMES A/S
Inventors:
Keiichi Ayabe, Tomoko Matsui, Aki Tomiki, Yuma Kurakata, Esben P. Friis, Jens E. Nielsen, Roland Alexander Pache
Abstract: Herein is reported a method for producing an antibody Fc-region conjugate comprising as first component an antibody Fc-region and as second component at least one binding entity that specifically binds to a target using a transpeptidase for enzymatic conjugation of the antibody Fc-region to at least one binding entity.
Abstract: Broth compositions prepared from poultry are disclosed. Selected poultry raw materials are processed to obtain a broth having high protein content. Certain specific amino acids are present in relatively higher concentration as compared to home-made broth and other commercial products. The disclosed broth compositions are effective in preventing and/or treating joint diseases and may also provide other nutritional and health benefits.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
August 23, 2022
Assignee:
INTERNATIONAL DEHYDRATED FOODS, INC.
Inventors:
Roger L. Dake, Stephanie Lynch, Paul L. Durham, Ryan J. Cady, Jordan L. Hawkins
Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.
Type:
Grant
Filed:
December 21, 2020
Date of Patent:
July 19, 2022
Assignee:
New England Biolabs, Inc.
Inventors:
Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
Abstract: A thermolysin solution has further improved stability as a result of the thermolysin solution containing thermolysin at a concentration that is 0.1 mg/mL or higher and the thermolysin solution having a pH that is adjusted to higher than 9.0. The thermolysin solution preferably has a pH in the range of 9.5-11.5.
Abstract: A DNA sequence encoding Der p1 protein having a particular base sequence is codon-optimized for the Pichia pastoris expression system, which is conducive to expressing Der p1 in Pichia pastoris. After gene optimization and adding an activating element to increase the expression of Der p1 in molecular level, it was found that Der p1 is expressed at a higher level as compared with the prior art and has biological activity similar to the natural protein.
Type:
Grant
Filed:
December 28, 2017
Date of Patent:
June 14, 2022
Inventors:
Bruce Yong Ma, Yu Fan, Anliang Wang, Jun Wang
Abstract: A liquid or dried granulated milk clotting aspartic protease enzyme composition and process for isolating a milk clotting aspartic protease enzyme of interest.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
February 1, 2022
Assignee:
CHR. HANSEN A/S
Inventors:
Martin Lund, Jonas Jacobsen, Johannes Maarten Van Den Brink
Abstract: The present disclosure relates to serine proteases cloned from Bacillus Akibai and Bacillus Clarkii, and variants thereof. Compositions containing the serine proteases are suitable for use in cleaning fabrics and hard surfaces, as well as in a variety of industrial applications.
Type:
Grant
Filed:
May 21, 2018
Date of Patent:
May 18, 2021
Assignee:
DANISCO US INC
Inventors:
Marc Kolkman, Rie Mejldal, Anja Hemmingsen Kellett Smith, Lilia Maria Babe, Richard R. Bott
Abstract: The present disclosure relates to proteases that are variants of a Bacillus gibsonii protease, the proteases comprising an amino acid sequence which has at least about 70% sequence identity to the amino acid sequence given in SEQ ID No. 1 over its entire length, and which has an amino acid substitution on at least one of the positions corresponding to the positions 12, 43, 122, 127, 154, 156, 160, 211 or 222, relating in each case to the numbering according to SEQ ID No. 1. The present disclosure also relates to the production and use thereof. Said type of proteases have a very good cleaning performance.
Type:
Grant
Filed:
June 1, 2017
Date of Patent:
March 9, 2021
Assignee:
Henkel AG & Co. KGaA
Inventors:
Daniela Herbst, Timothy O'Connell, Nina Mussmann, Inga Kerstin Vockenroth, Thomas Weber
Abstract: The present invention relates to protease variants, having improved properties compared to the parent protease, in particular variants of a serine protease belonging to family 53 derived from a strain of Meripilus giganteus. The variants according to the invention have in particular increased thermo-stability, e.g., increased residual activity after 30 min at a temperature in the range from 55 to 60° C. and/or increased thermal denaturation temperature, compared to the parent Meripilus giganteus protease. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Grant
Filed:
July 14, 2017
Date of Patent:
February 23, 2021
Assignee:
NOVOZYMES A/S
Inventors:
Keiichi Ayabe, Tomoko Matsui, Aki Tomiki, Yuma Kurakata, Esben P. Friis, Jens E. Nielsen, Roland Alexander Pache
Abstract: The present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
February 16, 2021
Assignee:
NOVOZYMES A/S
Inventors:
Frank Winther Rasmussen, Peter Kamp Hansen, Lars Lehman Hylling Christensen
Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
February 9, 2021
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin A. Maier, Klaus Charisse
Abstract: This invention relates to fabric and home care products comprising one or more cold water proteases and processes for making and using such products. Such compositions provide improved cleaning and freshness. Such cold water proteases may be derived from parent enzymes, including BPN? subtilisin and subtilisin derived from Bacillus lentus, by substitution, insertion and/or deletion of one or more of the parent enzymes' amino acids.
Type:
Grant
Filed:
December 13, 2017
Date of Patent:
January 26, 2021
Assignee:
The Procter & Gamble Company
Inventors:
Philip Frank Souter, Glenn Steven Ward, Viktor Yuryevich Alekseyev, Joshua Roy Basler, Luis Gustavo Cascao-Pereira, David A Estell, Ayrookaran J Poulose, James T Kellis, Jr., Alexander Pisarchik, Daniel Torres-Pazmino
Abstract: This disclosure provides a method for stabilizing both lipase and protease in liquid enzymatic laundry detergent, comprising steps of: first, self-assembling conjugated linoleic acid with protease and lipase, respectively, to form vesicles encapsulated protease and vesicles encapsulated lipase at a low Ca2+ concentration; then, mixing the solution of vesicles encapsulated protease and the solution of vesicles encapsulated lipase, and then partially cross-linking conjugated linoleic acid molecules on the vesicles' surface. The obtained enzyme vesicles, after being concentrated, can be used directly in liquid laundry detergent. The lipase in the liquid laundry detergent will not be degraded by protease, and the enzymes in vesicles are able to resist against surfactant inhibition. Thus, the enzyme activities can be maintained in the liquid laundry detergent, and the enzymatic vesicles will be broken to release enzymes, when the liquid laundry detergent is used at a higher Ca2+ concentration such as in tap water.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
November 17, 2020
Assignee:
Jiangnan University
Inventors:
Yun Fang, Yongmei Xia, Bei Wei, Yinxing Yan
Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
Type:
Grant
Filed:
February 12, 2016
Date of Patent:
September 1, 2020
Assignee:
HANSA BIOPHARMA AB
Inventors:
Christian Kjellman, Sofia Jarnum, Emma Nordahl
Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
August 18, 2020
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
Abstract: The present invention relates to a method for constructing a host cell expressing a polypeptide of interest from at least two ORF's stably integrated onto the chromosome of the host cell comprising the steps of: a) providing the at least two ORF's encoding the same polypeptide, wherein the at least two DNA sequences of the ORF's differ in at least one position; b) integrating the at least two ORF's in the same orientation on the host cell chromosome.
Type:
Grant
Filed:
September 23, 2013
Date of Patent:
May 5, 2020
Assignee:
Novozymes A/S
Inventors:
Steen Troels Jorgensen, Poul Erik Pedersen
Abstract: Disclosed are nucleotide sequences encoding thioesterase enzymes, methods for their production, their use in methods to form thioesters, and their use in methods of screening for other wild type bacteria capable of producing said thioesterase enzymes. Also disclosed are compositions comprising thioesters produced by the methods disclosed herein.
Type:
Grant
Filed:
July 31, 2018
Date of Patent:
April 14, 2020
Assignees:
Givaudan SA, Utah State University, Wisconsin Alumni Research Foundation
Inventors:
Tarun Bhowmik, Jeff Broadbent, Dennis Welker, James Steele, Mateo Budinich
Abstract: The subject invention provides novel devices and methods for the detection and quantification of neutrophil elastase activity in biological samples.
Type:
Grant
Filed:
June 28, 2010
Date of Patent:
March 3, 2020
Assignee:
University of Florida Research Foundation, Inc.
Abstract: The present invention relates to isolated polypeptides having protease activity and isolated nucleic acid sequences encoding the proteases. The invention also relates to nucleic acid constructs, vectors, and host cells, including plant and animal cells, comprising the nucleic acid sequences, as well as methods for producing and using the proteases, in particular the use of the proteases in animal feed.
Type:
Grant
Filed:
April 17, 2018
Date of Patent:
February 18, 2020
Assignee:
Novozymes A/S
Inventors:
Mary Ann Stringer, Tine Hoff, Peter Rahbek Oestergaard, Katrine Fruergaard Pontoppidan
Abstract: The invention includes Clostridial neurotoxin derivatives containing at least two light chain endopeptidase domains, and nucleic acids encoding such Clostridial neurotoxin derivatives. In preferred embodiments, the invention includes methods and compositions for the treatment of inflammatory disorders (such as arthritis); chronic pain, such as neuropathic pain and inflammatory pain through the use of such Clostridial neurotoxin derivatives, including those derived from an intact BoNT/A having an LC/E-derived endopeptidase joined to the LC/A endopeptidase.
Type:
Grant
Filed:
December 22, 2015
Date of Patent:
October 29, 2019
Assignee:
Dublin City University
Inventors:
James Oliver Dolly, Jiafu Wang, Jianghui Meng
Abstract: A food additive for improving sensory characteristics and providing nutritional value to cereals or cereal mixture with irregular surface, which consists of collagen peptides of terrestrial and marine animal origin, the composition of which is, in % by weight, from 14% to 18% essential amino acids, from 10% to 14% aspartic acid and from 18% to 22% glycine, from 23% to 27% proline and hydroxyproline, from 9% to 13% glutamic acid, from 6% to 10% arginine, and from 6% to 10% alamine, dissolved in 5% to 50% aqueous solution, which is used as a carrier for adding ingredients, to form a uniform glossy coating on the surface of cereals or cereal mixture.
Abstract: This invention relates to the use of clotting compositions containing prothrombin activators to produce high quality blood serum samples for pathology and other biological assays, and to containers containing such clotting compositions, and related methods of use.
Type:
Grant
Filed:
September 20, 2011
Date of Patent:
August 20, 2019
Inventors:
Paul Masci, John De Jersey, Martin Lavin, Julie Phillips, Goce Dimeski
Abstract: A plasma processing apparatus including: a monitor device which monitors a process quantity generated at plasma processing; a monitor value estimation unit which has monitor quantity variation models for storing change of a monitor value of the process quantity in accordance with the number of processed specimens and which estimates a monitor value for a process of a next specimen by referring to the monitor quantity variation models; and a control quantity calculation unit which stores a relation between a control quantity for controlling the process quantity of the vacuum processing device and a monitor value and which calculates the control quantity based on a deviation of the estimated monitor value from a target value to thereby control the process quantity for the process of the next specimen. Thus, stable processed results can be obtained even when variation occurs in processes.
Abstract: The invention relates to a method for enzymatically synthesizing an (oligo)peptide, comprising coupling (a) an (oligo)peptide C-terminal ester or thioester and (b) an (oligo)peptide nucleophile having an N-terminally unprotected amine, wherein the coupling is carried out in a fluid comprising water, and wherein the coupling is catalyzed by a subtilisin BPN? variant or a homolog thereof, which comprises the following mutations compared to subtilisin BPN? represented by SEQUENCE ID NO: 2 or a homolog sequence thereof: a deletion of the amino acids corresponding to positions 75-83; a mutation at the amino acid position corresponding to S221, the mutation being S221C or S221 selenocysteine; preferably a mutation at the amino acid position corresponding to P225 wherein the amino acid positions are defined according to the sequence of subtilisin BPN? represented by SEQUENCE ID NO: 2. Further, the invention relates to an enzyme suitable for use as a catalyst in a method of the invention.
Type:
Grant
Filed:
October 17, 2018
Date of Patent:
April 9, 2019
Assignee:
ENZYPEP B.V.
Inventors:
Peter Jan Leonard Mario Quaedflieg, Timo Nuijens, Jan Metske Van Der Laan, Dirk Barend Janssen, Ana Toplak, Bian Wu
Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
Type:
Grant
Filed:
April 12, 2017
Date of Patent:
March 5, 2019
Assignees:
Baxalta GmbH, Baxalta Incorporated
Inventors:
Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
Abstract: Disclosed is a process for preparing proteinaceous materials. The process comprises solubilizing fibrous protein by contacting it with an alkaline solution, ageing the resulting mixture to form a homogenous solution, and coagulating the resulting solution to form the proteinaceous material. The proteinaceous materials may be produced as, for example, fibers, films, sheets, coatings, particles, shapes, foams or composites.
Abstract: Low-pH automatic dishwashing detergent composition comprising an endoprotease having an isoelectric point from about 4 to about 9 and wherein the composition has a pH as measured in 1% weight aqueous solution at 25° C. of from about 5 to about 7.5.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
September 25, 2018
Assignee:
The Procter & Gamble Company
Inventors:
Alan Thomas Brooker, Philip Frank Souter, Colin Ure, Craig Adam Wilkinson, Lindsay Suzanne Bewick
Abstract: The present disclosure relates to a comprehensive model for expression of recombinant peptides by Pichia pastoris. The model uses an easily controllable variable called ‘critical nutrient ratio’ for obtaining a right balance between product synthesis and it's degradation during the fermentation process. The extra cellular concentration of precursor could be increased by about 10 folds and the degradation constants could be reduced by about 10-20 folds for intracellular and extracellular cases respectively by controlling critical nutrient ratio and addition of soya flour hydrolysate and EDTA.
Abstract: We describe the rational structure-based design of monomeric and dimeric forms of a nanobody-enhanced GFP (termed vsfGFP) that demonstrates ˜1.3-fold higher brightness than sfGFP in a monomeric form and ˜2.5-fold higher brightness in a dimeric form. These new vsfGFP variants demonstrate high stability and brightness in both bacterial and eukaryotic cells and are thus ideal for in vivo imaging applications. The combination of higher brightness, facile folding, stable expression, and tunable dimerization makes them ideal partners in essentially all in vitro applications already described for fluorescent proteins, including antibody fusion-based molecular probes, for which the higher brightness and tunable dimerization provide distinct advantages. Furthermore, the vsfGFP variants retain folding properties of sfGFP that enable bright fluorescence in oxidizing environments such as the bacterial periplasm.
Abstract: A kit for the determination of the thrombogenic power of human immunoglobulins contained in a biologically acceptable product. Also a process making it possible to determine the thrombogenic power linked to the presence of activated Factor XI and/or activated Factor IX and/or activated Factor XII, and/or activated Factor VII and/or activated Factor X in a sample capable of being administered to humans.
Type:
Grant
Filed:
November 18, 2011
Date of Patent:
February 13, 2018
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Abstract: The present invention is directed to methods and compositions that provide therapy for at least one medical condition that directly or indirectly affects cardiac muscle cells (also known as cardiomyocytes) in a mammalian individual, including humans, dogs, cats, horse pigs, and so forth. The medical condition may be of any kind, including a cardiac condition such as heart failure, cardiomyopathy, myocardial infarction, and so forth. The medical condition may have a cardiac condition as its primary symptom or cause or it may be a secondary symptom or cause. The individual may be male or female and may be of any age.
Type:
Grant
Filed:
December 9, 2014
Date of Patent:
August 15, 2017
Assignees:
Baylor College of Medicine, Texas Heart Institute
Inventors:
James F Martin, Yuka Morikawa, Todd Ryan Heallen, John Leach
Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
May 16, 2017
Assignee:
Sutro Biopharma, Inc.
Inventors:
Christopher D. Thanos, Christopher J. Murray, Junhao Yang, Heather Stephenson
Abstract: The invention is directed to a Ca2+ precipitable polypeptide tags and cassettes useful for purification of molecules from heterogeneous samples. The invention also relates to methods for bioseparation of molecules comprising Ca2+ precipitable tags and cassettes.
Type:
Grant
Filed:
October 11, 2013
Date of Patent:
January 24, 2017
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: A composition including an artificially synthesized antimicrobial peptide that is not present as a mature peptide in nature. The composition includes an artificially synthesized peptide that has an antimicrobial activity against at least one strain of bacteria or fungi and includes an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the amino acid sequence, and further including at least one species of pharmaceutically acceptable carrier.
Abstract: Proteases encompassing an amino acid sequence that is at least 70% identical to the amino acid sequence indicated in SEQ ID NO. 1 over its entire length, and exhibit the amino acid substitution I21V in the count in accordance with SEQ ID NO. 1, agents that encompass such proteases, display very good cleaning performance on protease-sensitive stains.
Type:
Grant
Filed:
March 10, 2011
Date of Patent:
June 14, 2016
Assignee:
Henkel AG & Co. KGaA
Inventors:
Petra Siegert, Ulrich Schwaneberg, Ronny Martinez, Marion Merkel, Astrid Spitz, Susanne Wieland, Hendrik Hellmuth, Karl-Heinz Maurer
Abstract: The invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, ?-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. The invention also provides compositions or products of manufacture comprising mixtures of enzymes comprising at least one enzyme of this invention.
Type:
Grant
Filed:
January 28, 2013
Date of Patent:
November 3, 2015
Assignee:
BP Corporation North America Inc.
Inventors:
Kevin A. Gray, Lishan Zhao, Michelle H. Cayouette
Abstract: An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13.
Type:
Grant
Filed:
October 30, 2014
Date of Patent:
August 18, 2015
Assignee:
THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Abstract: The present invention relates to an isolated mutant eubacterium comprising at least one mutation resulting in a substitution of at least one amino acid in the beta-subunit of the RNA-polymerase encoded for by the rpoB-gene providing an altered production of a product of interest when said production of a product of interest is compared to the production of the same product in an isogenic wild type strain grown at identical conditions, wherein the substitution of at least one amino acid occurs at any of positions 469, 478, 482, 485, or 487 of SEQ ID NO:2, or at the equivalent positions in any eubacterial RNA-polymerase beta-subunit family member. Another aspect of the invention relates to a process for producing at least one product of interest in a mutant eubacterium and to a use of the mutant eubacterium according to the invention for producing at least one product of interest.
Abstract: The present invention relates to proteases having at least 75% identity to a protease derived from Thermoascus aurantiacus and comprises at least one modification in the amino acid sequence thereof. These protease variants have improved thermostability. The invention also relates to DNA encoding these proteases, methods of their production, as well as the use thereof.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
May 26, 2015
Assignee:
NOVOZYMES A/S
Inventors:
Tomoko Matsui, Allan Noergaard, Thomas Agersten Poulsen, John Matthews
Abstract: The present invention provides methods for protein engineering and serine protease variants produced there from. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.
Type:
Application
Filed:
November 10, 2014
Publication date:
May 14, 2015
Applicant:
DANISCO US INC.
Inventors:
Wolfgang Aehle, Luis G. Cascao-Pereira, David A. Estell, Frits Goedegebuur, James T. Kellis, JR., Ayrookaran J. Poulose, Brian F. Schmidt
Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
Type:
Grant
Filed:
August 16, 2012
Date of Patent:
May 12, 2015
Assignees:
Novozymes A/S, Novozymes Inc
Inventors:
Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory